Evidence map›Paper›PMID 33564966›Full record

ArticleInternational journal of hematology2021

Salvage therapy with 2-chlorodeoxyadenosine for refractory and relapsed pediatric Langerhans cell histiocytosis: an updated nationwide survey in Japan.

Maki Taniguchi, Kenichi Sakamoto, Yoko Shioda, Takehiko Doi, Ko Kudo, Hisanori Fujino, Kazuko Kudo, Akira Morimoto

Abstract readLetter
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Maki TaniguchiDepartment of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Kenichi SakamotoChildren's Cancer Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. sakamoto-k@ncchd.go.jp.ORCID http://orcid.org/0000-0003-1499-538X
Yoko ShiodaChildren's Cancer Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
Takehiko DoiDepartment of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Ko KudoDepartment of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hisanori FujinoDepartment of Pediatrics, Osaka Red Cross Hospital, Osaka, Japan.
Kazuko KudoDepartment of Pediatrics, Fujita Health University, Toyoake, Japan.
Akira MorimotoDepartment of Pediatrics, Jichi Medical University School of Medicine, Shimotsuke, Japan.
Fujita Health University · JPHiroshima University · JPNational Center For Child Health and Development · JPJichi Medical University · JPOsaka Red Cross Hospital · JP

Funding

Japan Intractable Diseases (Nanbyo) Research Foundation 2019B02
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsChildChild, PreschoolCladribineFemaleHistiocytosis, Langerhans-CellHumansImmunosuppressive AgentsInfantJapanMaleSalvage TherapySecondary PreventionAntineoplastic AgentsCladribineImmunosuppressive Agents2-chlorodeoxyadenosineLangerhans cell histiocytosisRefractory/relapse

Identifiers

PMID33564966
OpenAlexW3128656091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.